Concert Pharmaceuticals (NASDAQ:CNCE) Rating Lowered to Hold at Zacks Investment Research
Concert Pharmaceuticals (NASDAQ:CNCE) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Monday, Zacks.com reports.
According to Zacks, “Concert Pharmaceuticals Inc. is a biopharmaceutical company. It is focused on applying its DCE Platform (R) to create novel small molecule drugs. The Company manufactures drugs in various therapeutic areas such as hot flashes, HIV, renal hepatic, neuropathic pain, MRSA infection, and schizophrenia, multiple tumors, and hyperparathyroidism. Concert Pharmaceuticals Inc. is based in United States. “
Other analysts have also issued research reports about the stock. Janney Montgomery Scott reaffirmed a “buy” rating and set a $10.00 target price (down previously from $13.00) on shares of Concert Pharmaceuticals in a report on Monday, September 30th. BidaskClub lowered shares of Concert Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, September 28th. SunTrust Banks reduced their target price on shares of Concert Pharmaceuticals from $30.00 to $20.00 and set a “buy” rating on the stock in a report on Monday, September 30th. Mizuho reaffirmed a “buy” rating and set a $18.00 target price on shares of Concert Pharmaceuticals in a report on Friday, November 8th. Finally, ValuEngine cut shares of Concert Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Monday, November 4th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and six have assigned a buy rating to the company’s stock. Concert Pharmaceuticals has a consensus rating of “Buy” and an average target price of $15.22.
Concert Pharmaceuticals (NASDAQ:CNCE) last posted its earnings results on Thursday, November 7th. The biotechnology company reported ($0.72) EPS for the quarter, topping the consensus estimate of ($0.85) by $0.13. The company had revenue of $0.01 million during the quarter, compared to the consensus estimate of $0.35 million. Concert Pharmaceuticals had a negative net margin of 7,291.37% and a negative return on equity of 55.06%. On average, analysts anticipate that Concert Pharmaceuticals will post -3.21 EPS for the current fiscal year.
In other news, Director Heek Christi Van acquired 5,000 shares of Concert Pharmaceuticals stock in a transaction on Tuesday, October 8th. The stock was acquired at an average cost of $5.90 per share, for a total transaction of $29,500.00. Following the purchase, the director now owns 5,000 shares in the company, valued at $29,500. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 11.00% of the stock is currently owned by company insiders.
A number of large investors have recently added to or reduced their stakes in the business. Quantamental Technologies LLC bought a new position in shares of Concert Pharmaceuticals in the second quarter worth about $27,000. Flagship Harbor Advisors LLC grew its stake in shares of Concert Pharmaceuticals by 163.2% during the 3rd quarter. Flagship Harbor Advisors LLC now owns 5,000 shares of the biotechnology company’s stock worth $29,000 after purchasing an additional 3,100 shares during the period. Aperio Group LLC acquired a new stake in shares of Concert Pharmaceuticals during the 2nd quarter worth approximately $43,000. State Board of Administration of Florida Retirement System acquired a new stake in shares of Concert Pharmaceuticals during the 2nd quarter worth approximately $128,000. Finally, Parametric Portfolio Associates LLC grew its stake in shares of Concert Pharmaceuticals by 10.6% during the 2nd quarter. Parametric Portfolio Associates LLC now owns 11,349 shares of the biotechnology company’s stock worth $136,000 after purchasing an additional 1,089 shares during the period. Institutional investors and hedge funds own 71.29% of the company’s stock.
Concert Pharmaceuticals Company Profile
Concert Pharmaceuticals, Inc operates as a clinical stage biopharmaceutical company. The company discovers and develops novel small molecule drugs for use in the treatment autoimmune and inflammatory diseases, and central nervous systems disorders. Its product candidates include AVP-786, a combination of deudextromethorphan and an ultra-low dose of quinidine, which is in Phase 3 clinical trials for the treatment of neurologic and psychiatric disorders, including agitation associated with Alzheimer's disease; CTP-730, a deuterated analog of apremilast that has completed the Phase 1 clinical trials for the treatment of inflammation or cancer; JZP-386, a once-nightly oxybate product; and CTP-543, which is in Phase 1 clinical trials for use in the treatment of alopecia areata.
Featured Article: What is the G-20?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Concert Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Concert Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.